Cost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial.
Anita PatelMargaret HeslinDavid L ScottDominic StringerFraser BirrellFowzia IbrahimPublished in: Arthritis care & research (2020)
Starting treatment with csDMARDs, rather than TNFi, achieves similar outcomes at significantly lower costs. Patients with active RA and who meet the National Institute for Health and Care Excellence criteria for expensive biologics can be treated with combinations of intensive csDMARDs in a cost-effective manner.
Keyphrases
- rheumatoid arthritis
- phase iii
- healthcare
- disease activity
- double blind
- study protocol
- quality improvement
- phase ii
- ankylosing spondylitis
- open label
- clinical trial
- public health
- placebo controlled
- interstitial lung disease
- palliative care
- mental health
- randomized controlled trial
- cross sectional
- type diabetes
- pain management
- risk assessment
- climate change
- insulin resistance
- adipose tissue
- health promotion
- weight loss